Get the Stockscreener App
11.41
2.65%
-0.31
After Hours:
11.41
Emergent Biosolutions Inc stock is traded at $11.41, with a volume of 568.00K.
It is down -2.65% in the last 24 hours and up +5.55% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$11.72
Open:
$11.77
24h Volume:
568.00K
Relative Volume:
0.53
Market Cap:
$599.25M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.773
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-4.12%
1M Performance:
+5.55%
6M Performance:
+72.88%
1Y Performance:
+31.30%
1-Day Range:
$11.34
$11.85
1-Week Range:
$11.16
$12.09
52-Week Range:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
11.41 | 615.53M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - The Manila Times
Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan
Energy Moves: Can Emergent BioSolutions Inc stock weather global recessionEarnings Growth Summary & Trade Opportunity Analysis Reports - moha.gov.vn
Emergent BioSolutions Inc Stock Analysis and ForecastEvening Star Patterns & Low Risk Capital Growth Plans - earlytimes.in
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
EBS (NYSE: EBS) holder files Form 144 to sell 32,848 shares - Stock Titan
What makes Emergent BioSolutions Inc. stock appealing to growth investorsTrade Risk Report & AI Driven Stock Reports - Newser
Emergent Biosolutions Inc. $EBS Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
How cyclical is Emergent BioSolutions Inc. (ER4) stock compared to rivalsMarket Risk Report & Free Reliable Trade Execution Plans - Newser
Will Emergent BioSolutions Inc. stock split again soonBull Run & Daily Risk Controlled Trade Plans - Newser
Will Emergent BioSolutions Inc. stock reach Wall Street targets2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesTrade Entry Summary & Daily Growth Stock Investment Tips - Newser
Will Emergent BioSolutions Inc. (ER4) stock extend growth storyJuly 2025 EndofMonth & Reliable Price Action Trade Plans - Newser
Published on: 2025-12-04 04:37:47 - Newser
Is Emergent BioSolutions Inc. (ER4) stock protected from inflationJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Will Emergent BioSolutions Inc. (ER4) stock top growth indexesM&A Rumor & AI Driven Price Forecasts - Newser
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2025-12-03 01:19:03 - Newser
How Emergent BioSolutions Inc. stock compares to market leadersJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Why ETFs are accumulating Emergent BioSolutions Inc. stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Emergent BioSolutions Inc. stock is popular among millennialsInflation Watch & Weekly Top Stock Performers List - Newser
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedDip Buying & Advanced Swing Trade Entry Alerts - Newser
Emergent BioSolutions (EBS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock chartsPortfolio Value Report & Risk Controlled Swing Alerts - Newser
Why Emergent BioSolutions Inc. stock trades below fair value2025 Volatility Report & Weekly Chart Analysis and Guides - Newser
Will Emergent BioSolutions Inc. stock justify high valuationWatch List & Daily Market Momentum Tracking - Newser
Emergent Biosolutions (NYSE:EBS) Upgraded at Wall Street Zen - MarketBeat
Emergent Biosolutions Inc. diskutieren - sharewise.com
EBS (Emergent BioSolutions) Debt-to-EBITDA : 1.72 (As of Sep. 2025) - GuruFocus
Stock Report: Why Emergent BioSolutions Inc. stock is a must watch tickerEarnings Overview Report & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Should Emergent BioSolutions Inc. (NYSE:EBS) Focus On Improving This Fundamental Metric? - 富途牛牛
Performance Recap: How risky is Emergent BioSolutions Inc. stock nowPortfolio Value Summary & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt - simplywall.st
Emergent Biosolutions (NYSE:EBS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
With Emergent BioSolutions Stock Surging, Have You Considered The Downside? - Trefis
Emergent Biosolutions marks 10 years since FDA approval of NARCAN with Emmitt Smith - Traders Union
Why Emergent BioSolutions Inc. stock could outperform in 2025Weekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will Emergent BioSolutions Inc. stock deliver consistent dividends2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Emergent BioSolutions Inc. stock deliver consistent EPS growth2025 Volume Leaders & Verified Entry Point Signals - newser.com
Will Emergent BioSolutions Inc. stock gain from green policiesJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
How Emergent BioSolutions Inc. stock compares with tech leadersPortfolio Update Summary & Entry Point Strategy Guides - newser.com
How dovish Fed policy supports Emergent BioSolutions Inc. stockJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockPrice Action & AI Driven Stock Movement Reports - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenariosPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
Understanding Emergent BioSolutions Inc.’s price movement2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):